731 results about "Skeletal muscle" patented technology

Apparatus for actuating a skeletal muscle of a patient is provided. The apparatus typically includes a plurality of electrodes, which are adapted to be placed in a vicinity of a motor nerve that innervates the skeletal muscle. A control unit, is preferably adapted to drive a current between two or more of the plurality of electrodes, and to configure the current such that a first subset of axons in the nerve is excited by the current and such that a second subset of axons in the nerve is not excited by the current.

A method is disclosed for enhanced vaccination and genetic vaccination of mammals. The vaccination is accomplished by delivering molecules such as proteins and nucleic acids into skeletal muscle and other cells residing in the skeletal muscle in vivo. The protein or nucleic acid is first injected into the muscle at one or multiple sites. Immediately or shortly after injection, electrodes are placed flanking the injection site and a specific amount of electrical current is passed through the muscle. The electrical current makes the muscle permeable, thus allowing the pharmaceutical drug or nucleic acid to enter the cell. The efficiency of transfer permits robust immune responses using DNA vaccines and produces sufficient secreted proteins for systemic biological activity to be observed.

[Problem to be Solved]

The problem to be solved by the present invention is to reduce the load applied to the wearer by correcting a parameter in correspondence with detectivity of biosignals.

[Means to Solve Problem]

The calibration controlling part 162 of the movement assisting apparatus 10 enables the power amplifying part 158 to apply a driving force of the driving source 140 as a load (input torque) from the load generating part 164 to the wearer 12 when the wearer 12 wears the movement assisting wearing device. Then, the wearer 12 applied with the driving force of the driving source 140 generates power from the skeletal muscles by performing a predetermined calibration operation. Accordingly, the physical phenomenon detecting part 142 detects joint angle along with the calibration operation, and the biosignal detecting part 144 detects myoelectric signals. In the parameter correction part 156, a parameter K is corrected based on the difference between the load (input torque) and the driving force (muscular strength) being calculated by the difference deriving part 154 with respect to the phase identified by the phase identifying part 152.

The present invention describes compositions and methods for treating, preventing and improving the appearance of skin, particularly, treating, preventing, ameliorating, reducing and/or eliminating fine lines and/or wrinkles of skin, wherein the compositions include limonoid constituents which inhibit acetylcholine release at neuromuscular junctions of skeletal muscle so as to relax the muscles involved with wrinkling, folding and creasing of skin, e.g., facial movement and expression. The limonoids preferably include the plant alkaloids toosendanin and azadirachtin. The compositions, which also are used to treat hyperhidrosis, are preferably applied to the skin, or are delivered by directed means to a site in need thereof.

A preferably non-electrical nerve communication enhancement tool that sends specific, pre-timed, controlled vibrational and/or acoustical stimulation frequencies to the body to enhance nerve communication for the purpose of assisting in proper function of skeletal muscle, smooth muscle, sympathetic and parasympathetic nervous systems, and facilitating rapid and improved cerebellar timing circuit and related cerebellar learning mechanism pathways such as the inferior olivary-Purkinje-Thalamus cell system and other similar neuronal pools, to improve muscle memory, coordinated functional neuron-musculo-skeletal performance improvement, enhance blood flow, increased range of motion, flexibility, strength and dexterity, neuromuscular re-education, muscle tone recovery, pain modulation, improved eye-hand coordination, gait improvement, balance and stability gains, kinetic chain integration, neurological performance enhancement, sensory dysfunction reduction, and improvement in mental and cognitive function.

A biological function assist apparatus composed an electromechanically-based system wrapped in protective coating and controlled by a controller, which also provides power to the electromechanically-based system. The electromechanically-based system can be formed as a mesh using MEMS or a larger electromechanically grid and wrapped around a failing heart, or the electromechanical system can be formed in a circle forming an artificial valve (e.g., sphincter). The electromechanically-based system can operate as a bone-muscle interface, thereby functioning in place of tendons.

Systems and methods define an index of risk for cardiac disease by detecting cellular derangements that may lead to cardiomyopathy, heart rhythm disorders or ischemic heart disease. The markers include fluctuations or abnormal rate-behavior of electrical, mechanical or other measurable biosignals. The invention operates in modes that can be applied to prevent atrial fibrillation or the risk for ventricular arrhythmias. Alternative embodiments are applied to tissue outside the heart such as skeletal muscle, smooth muscle, the central nervous system, the respiratory system, the urogenital system and the gastrointestinal system.

The invention is directed to topical formulations and methods of treating a migraines and/or cluster headaches, muscle sprains, muscle spasms, spasticity, tension headaches, tension related migraines and related conditions associated with muscle tension and pain with a therapeutically effective amount of an ergot alkaloid, skeletal muscle relaxant, serotonin agonist, combinations thereof, pharmaceutically acceptable salt thereof, prodrugs thereof or derivative thereof.

A method to control skeletal muscles generally comprising generating at least one coded waveform signal that is substantially similar to at least one coded waveform signal that is generated in the body and operative in the control of at least a first skeletal muscle and transmitting the generated waveform signal to a subject to control the first skeletal muscle.

An apparatus for determining tissue versus fluid components of an organ include a detector that generates a detector signal based on electrical signals derived from tissue and fluid. The apparatus includes a signal processor in communication with the detector which subtracts in real time a tissue component from the detector signal and produces a fluid volume signal. A method for monitoring a patient's fluid volume of a patient's organ. An apparatus for monitoring a patient's organ. A method for monitoring a patient's organ. A method to piggyback an admittance system onto a AICD/Bi-ventricular Pacemaker for a heart of a patient, in particular a weakened heart having features consistent with congestive heart failure. An apparatus for monitoring an organ, such as a heart, lungs, brain, skeletal muscle, and bladder of a patient which includes a detector which detects the admittance of the organ. The apparatus includes a transmitter in communication with the detector which transmits a wireless signal indicative of the admittance of the organ. A method for monitoring an organ of a patient includes the steps of detecting with a detector the admittance of the organ. There is the step of transmitting with a transmitter in communication with the detector a wireless signal indicative of admittance of the organ.

An apparatus, according to various aspects of the present invention, produces contractions in skeletal muscles of a target to impede locomotion by the target. The apparatus is used with a provided deployment unit that deploys an electrode away from the apparatus. The electrode conducts a current through the target. The apparatus includes a terminal; a producing sub-system for producing an electric arc to warn the target without conducting a current through the target; a conducting sub-system for conducting the current in series through the terminal and through the target; an initiating sub-system for initiating deployment of the electrode; and an operator interface. The operator interface facilitates selecting one or more cartridges of a set of cartridges to provide a stimulus signal to a target and/or display an arc.

The present invention relates to a device and system to measure and assess superficial skeletal muscle mechanical and neuromuscular contractile characteristics, and interpret the results to provide metrics with quantifiable and qualitative descriptors relating to muscle function. The present device provides a further type of mechanomyography and a new use for acceleromyography by measuring the mechanical muscle movement of an involuntary stimulated muscle from an automated electro-stimulation protocol to determine muscle contractile properties. Muscle twitch response during the latent, contraction and relaxation phase is measured using an array of multiple accelerometers on a sensor pad to assess and diagnose muscle. function from various measurements. This information is processed using algorithms to determine muscle function abnormalities, muscle activation patterns, muscle symmetry of lateral muscle pairs, muscle synchronization of antagonist muscle, muscle force, muscle acceleration, muscle speed, muscle tone, muscle fatigue, muscle power/torque and muscle efficiency.

A device for treatment of patients with disturbed posture and motor activity comprises shoulder, pelvic, knee, pedal, elbow, hand, and finger supports (1), all of them being interconnected by fixing elements, which are shaped as elastic tie-members (2) and placed on the surface of the patient's body in antagonistic pairs so as to follow anatomical arrangement of skeletal muscles. Each of the tie-members (2) is connected to two of the supports (1) and comprises an adjuster (3) of its tension, which is interposed between the tie-member (2) and one of the supports (1) through a lock (5).

Disclosed are methods, compositions, and cells useful for increasing insulin sensitivity, as well as lack of insulin production in a host in need thereof. One aspect of the invention discloses methods of increasing skeletal muscle perfusion through administration of cells capable of directly and/or indirectly stimulatory of angiogenesis and/or vascular responsiveness. Another aspect provides means of increasing sensitivity to insulin through administration of a cell composition capable of integrating into host insulin responsive tissue and upregulating responsiveness either through mobilization of host cells capable of responding to insulin, mobilization of host cells capable of endowing insulin responsiveness on other host cells, exogenously administered cells taking the role of insulin responsiveness, or exogenously administered cells endowing insulin responsiveness on other host cells. Another aspect comprises modifying said host to allow for concurrent insulin sensitization and upregulated production of insulin.

This invention discloses isolated short peptides comprising the amino acid sequence Cys-Glu-Phe-His (CEFH) and analogs thereof as well as compositions comprising CEFH peptides and analogs thereof. The CEFH peptides disclosed herein are effective in mediating the denitration of 3-nitrotyrosines (3-NT) in cellular proteins thereby preventing tissue damage associated with excess nitric oxide (NO) and its reactive species. The CEFH peptides disclosed herein are useful in the treatment of ischemia/reperfusion (I/R) injury of various tissues (e.g., I/R injury of heart muscle associated with heart attack or cardiac surgery, I/R injury of brain tissue associated with stroke, I/R injury of liver tissue, skeletal muscles, etc.), septic shock, anaphylactic shock, neurodegenerative diseases (e.g., Alzheimer's and Parkinson's diseases), neuronal injury, atherosclerosis, diabetes, multiple sclerosis, autoimmune uveitis, pulmonary fibrosis, oobliterative bronchiolitis, bronchopulmonary dysplasia (BPD), amyotrophic lateral sclerosis (ALS), sepsis, inflammatory bowel disease, arthritis, allograft rejection, autoimmune myocarditis, myocardial inflammation, pulmonary granulomatous inflammation, influenza- or HSV-induced pneumonia, chronic cerebral vasospasm, allergic encephalomyelitis, central nervous system (CNS) inflammation, Heliobacterium pylori gastritis, necrotizing entrerocolitis, celliac disease, peritonitis, early prosthesis failure, inclusion body myositis, preeclamptic pregnancies, skin lesions with anaphylactoid purpura, nephrosclerosis, ileitis, leishmaniasis, cancer, and related disorders.